Crescent Biopharma, Inc. (CBIO )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CBIO
- Company Crescent Biopharma, Inc.
- Price $12.69
- Changes Percentage 10.64
- Change 1.22
- Day Low $11.5
- Day High $13.51
- Year High $29
- Year Low $8.72
- Market Cap $349,695,373
- Price Avg 50 EMA (D) $11.53
- Price Avg 200 EMA (D) $14.06
- Exchange NASDAQ
- Volume 120,228
- Average Volume 197,898
- Open $11.5
- Previous Close $11.47
- EPS 0
- PE 0.00
- Earnings Announcement 2026-03-25 12:00:00
- Shares Outstanding $27,556,767
Company brief: CRESCENT BIOPHARMA, INC. (CBIO )
- Healthcare
- Biotechnology
- Dr. Nassim Usman Ph.D.
- https://www.catalystbiosciences.com
- US
- N/A
- 04-12-2006
- US4037831033
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
CBIO Corporation News
Crescent Biopharma to Present at March Investor Conferences
globenewswire.com -- WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing t...